23 patents
Utility
Hepatitis b core protein modulators
14 Nov 23
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
Filed: 4 Jan 21
Utility
Pyrazole Carboxamide Compounds for Treatment of HBV
21 Sep 23
The present disclosure provides, in part, pyrazole carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
Simon Nicolas HAYDAR, Thilo HECKRODT, Michael WALKER, Min ZHONG
Filed: 21 Apr 21
Utility
Cyclic Sulfamide Compounds for Treatment of HBV
9 Mar 23
The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
Michael Walker, Leping Li, Simon Nicolas Haydar
Filed: 5 Sep 19
Utility
Hepatitis B Core Protein Modulators
9 Feb 23
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
Filed: 4 Jan 21
Utility
5-membered heteroaryl carboxamide compounds for treatment of HBV
24 Jan 23
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
Simon Nicolas Haydar, Leping Li, Mark G. Bures, Roopa Rai, Lynne Bannen, Michael Walker
Filed: 22 Oct 19
Utility
Hepatitis B Core Protein Allosteric Modulators
19 Jan 23
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
Filed: 21 Jan 21
Utility
Cyclic Sulfamide Compounds and Methods of Using Same
12 Jan 23
The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
William W. Turner, Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
Filed: 14 Jan 21
Utility
Pharmaceutical Compositions for the Treatment of HBV
4 Aug 22
The present disclosure provides, in part, pharmaceutical compositions that comprise a spray dried dispersion which contains the disclosed compound, and optionally, pharmaceutical excipients.
Lee D. ARNOLD, George Koan WONG, Kirk HENNE, James Francis HULVAT, Sanjay KONAGURTHU, Ian Scott MCINTOSH, Matthew David WESSEL, Thomas REYNOLDS, Richard J. COLONNO, Uri A. LOPATIN
Filed: 22 May 20
Utility
Cyclic Sulfamide Compounds for Treatment of HBV
17 Mar 22
The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
Michael Walker, Leping Li, Simon Nicolas Haydar
Filed: 5 Sep 19
Utility
Hepatitis B Core Protein Modulators
27 Jan 22
William W. Turner, Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
Filed: 14 Jan 21
Utility
Process for Making Hepatitis B Core Protein Modulators
9 Dec 21
Leping Li, Lee D. Arnold, Sreenivasa Reddy
Filed: 14 Jan 21
Utility
Cyclic sulfamide compounds and methods of using same
3 Aug 21
The present disclosure provides, in part, cyclic sulfamide compounds, and pharmaceutical compositions thereof, useful as modulators of Hepatitis B (HBV) core protein, and methods of treating Hepatitis B (HBV) infection.
William W. Turner, Jr., Leping Li, Simon Nicolas Haydar, Mark G. Bures, Roopa Rai, Samson Francis, Lee D. Arnold
Filed: 1 Mar 18
Utility
Process for making Hepatitis B core protein modulators
22 Jun 21
Leping Li, Lee D. Arnold, Sreenivasa Reddy Mundla
Filed: 13 Mar 18
Utility
Process for making Hepatitis B core protein modulators
18 May 21
Leping Li, Lee D. Arnold, Sreenivasa Reddy Mundla
Filed: 13 Mar 18
Utility
Hepatitis B core protein modulators
27 Apr 21
William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
Filed: 14 Sep 17
Utility
Hepatitis B core protein modulators
6 Apr 21
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
Filed: 30 May 19
Utility
Hepatitis B core protein allosteric modulators
16 Mar 21
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
Filed: 27 Apr 18
Utility
Compositions Comprising Bacterial Species and Methods Related Thereto
4 Mar 21
The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp.
Peyman Akbari, Ali Akin, Rounak Feigelman, Wayne Herber, Jason Hudak, Jun Ma, Jackie Papkoff, Lauren Wong
Filed: 28 Aug 20
Utility
Hepatitis B core protein modulators
7 Sep 20
The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
William Turner, Hans Maag, Samson Francis
Filed: 14 Sep 16
Utility
Methods and Compositions for Treating Gastrointestinal and Inflammatory Disorders
8 Jul 20
The disclosure relates generally to bacterial strains and bacterial strain mixtures, e.g., Eubacterium, Bacteroides, and Roseburia bacterial strains and mixtures thereof.
Jackie Papkoff, Jun Ma
Filed: 12 Sep 19